Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control

被引：1
|
作者：
Blauvelt, Andrew [1 ]
Langley, Richard G. [2 ]
Peris, Ketty [3 ]
Silvestre, Juan Francisco [4 ]
Katoh, Norito [5 ]
Tauber, Marie [6 ,7 ]
Pinter, Andreas [8 ]
Ameen, Mahreen [9 ]
Gooderham, Melinda [10 ,11 ]
Oland, Christian Bjerregard [12 ]
Tindberg, Ann-Marie [12 ]
Gjerum, Le [12 ]
Reich, Kristian [13 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dalhousie Univ, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
[3] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy
[4] Hosp Gen Univ Dr Balmis, Dermatol Dept, ISABIAL, Alicante, Spain
[5] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan
[6] Lyon Sud Hosp, Dept Allergol & Clin Immunol, Lyon, France
[7] INSERM, CIRI, U1111, Lyon, France
[8] Goethe Univ Frankfurt Main, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[9] Royal Free London Natl Hlth Serv Fdn Trust, London, England
[10] SKiN Ctr Dermatol, Peterborough, ON, Canada
[11] Queens Univ, Dept Dermatol, Kingston, ON, Canada
[12] LEO Pharma AS, Ballerup, Denmark
[13] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
long-term; efficacy; ECZTEND; tralokinumab; moderate-to-severe;
D O I：
10.1093/bjd/ljad498.050
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
551
引用
收藏
页码：II48 / II49
页数：2
相关论文
共 50 条
  • [31] Long-term Use of Systemic Treatments for Moderate-to-Severe Atopic Dermatitis in Adults: A Monocentric Retrospective Study
    Vedie, Anne-Laure
    Ezzedine, Khaled
    Amazan, Emmanuelle
    Boralevi, Franck
    Milpied, Brigitte
    Taieb, Alain
    Seneschal, Julien
    ACTA DERMATO-VENEREOLOGICA, 2016, 96 (06) : 802 - 806
  • [32] Long-Term Improvement in Patients with moderate to severe atopic Dermatitis treated with Tralokinumab: An ECZTEND Interim Analysis
    Beissert, Stefan
    Blauvelt, Andrew
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Herranz, Pedro
    Pink, Andrew
    Peris, Ketty
    Fangel, Stine
    Saeki, Hidehisa
    Wollenberg, Andreas
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 29 - 30
  • [33] Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
    Chovatiya, Raj
    Ribero, Simone
    Wollenberg, Andreas
    Park, Chang Ook
    Silvestre, Juan Francisco
    Hong, H. Chih-Ho
    Seneschal, Julien
    Saeki, Hidehisa
    Thyssen, Jacob P.
    Oland, Christian Bjerregard
    Gjerum, Le
    Maslin, Douglas
    Blauvelt, Andrew
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2025,
  • [34] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years
    Wollenberg, Andreas
    Soong, Weily
    Goooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
  • [35] TRALOKINUMAB PLUS TOPICAL CORTICOSTEROIDS AS NEEDED PROVIDES PROGRESSIVE IMPROVEMENTS IN EXTENT AND SEVERITY OF MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Alexis, Andrew F.
    Zirwas, Matthew
    Pinter, Andreas
    Adam, David N.
    Chiricozzi, Andrea
    Pink, Andrew E.
    Mark, Thomas
    Tindberg, Ann-Marie
    Silverberg, Jonathan I.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 63 - 64
  • [36] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: open-label extension study
    Blauvelt, A.
    Wollenberg, A.
    Beck, L. A.
    Chen, Z.
    Vakil, J.
    Khokhar, F. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E120 - E121
  • [37] Impact of dupilumab treatment on seasonal disease severity in adults with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Simpson, Eric L.
    Ramien, Michele
    Tang, Mark
    Joyce, Joel C.
    Praestgaard, Amy
    Rossi, Ana B.
    Clearfield, Drew
    Zhang, Annie
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [38] Dupilumab monotherapy provides long-term improvement in all Patient-Oriented Eczema Measure items in adults with moderate-to-severe atopic dermatitis
    Hussain, I.
    Bissonnette, R.
    Sanchez-Carazo, J. L.
    Ahn, K. J.
    Kataoka, Y.
    Praestgaard, A.
    Thomas, R. B.
    Bego-Le Bagousse, G.
    Wilson, G.
    Rossi, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E157 - E158
  • [39] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Zheng, Y.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 72
  • [40] Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
    Khattri, Saakshi
    Brunner, Patrick M.
    Garcet, Sandra
    Finney, Robert
    Cohen, Steven R.
    Oliva, Margeaux
    Dutt, Riana
    Fuentes-Duculan, Judilyn
    Zheng, Xiuzhong
    Li, Xuan
    Bonifacio, Kathleen M.
    Kunjravia, Norma
    Coats, Israel
    Cueto, Inna
    Gilleaudeau, Patricia
    Sullivan-Whalen, Mary
    Suarez-Farinas, Mayte
    Krueger, James G.
    Guttman-Yassky, Emma
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (01) : 28 - 35
12345